Koa Shoji Holdings
9273.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-06 | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|---|
| Revenue | ¥24.7bn | ¥23.3bn | ¥22.1bn | ¥22.1bn | ¥20.4bn | ¥17.8bn |
| Operating income | ¥5.5bn | ¥5.4bn | ¥4.4bn | ¥4.2bn | ¥3.8bn | ¥3.4bn |
| Ordinary income | ¥5.5bn | ¥5.4bn | ¥4.4bn | ¥4.1bn | ¥3.8bn | ¥3.4bn |
| Net income (owners) | ¥3.7bn | ¥3.6bn | ¥2.9bn | ¥2.7bn | ¥2.4bn | ¥2.1bn |
| Total assets | ¥39.5bn | ¥36.1bn | ¥32.0bn | ¥28.5bn | ¥26.2bn | ¥24.8bn |
| Net assets / equity | ¥31.2bn | ¥28.1bn | ¥25.1bn | ¥20.9bn | ¥18.7bn | ¥16.7bn |
| Operating cash flow | ¥7.6bn | ¥3.8bn | ¥3.8bn | ¥2.7bn | ¥2.1bn | ¥3.1bn |
| EPS (basic) | ¥89 | ¥86.38 | ¥74.14 | ¥67.83 | ¥59.55 | ¥53.94 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-07-01 → 2026-06-30 | Annual | 203 figures · EDINET |
| 2025-07-01 → 2025-12-31 | Half-year | 71 figures · EDINET |
| 2024-07-01 → 2025-06-30 | Annual | 203 figures · EDINET |
| 2024-07-01 → 2024-12-31 | Half-year | 71 figures · EDINET |
| 2023-07-01 → 2024-06-30 | Annual | 203 figures · EDINET |
| 2023-07-01 → 2024-03-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-07-01 → 2023-12-31 | Quarterly Q2 | 73 figures · EDINET |
| 2023-07-01 → 2023-09-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-07-01 → 2023-06-30 | AnnualAmended | 203 figures · EDINET |
| 2022-07-01 → 2023-06-30 | Annual | 203 figures · EDINET |
| 2022-07-01 → 2023-03-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-07-01 → 2022-12-31 | Quarterly Q2 | 73 figures · EDINET |
| 2022-07-01 → 2022-09-30 | Quarterly Q1 | 47 figures · EDINET |
| 2021-07-01 → 2022-06-30 | Annual | 203 figures · EDINET |
18 more reports are still being processed.
Segments · FY ended 2026-06
| Segment | External sales | Profit |
|---|---|---|
| Drug Substance Sales Business | ¥15.7bn | ¥3.3bn |
| Pharmaceutical Marketing Business | ¥9.0bn | ¥2.1bn |
| Adjustments & eliminations | — | ¥40m |
| Total | ¥24.7bn | ¥5.4bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.